Elutia Inc.
ELUT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001708527
No open-market purchases or sales by Elutia Inc. insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $13.8M in total; no superinvestor holds it.
13F holders, Q3 2023
Institutional positions in Elutia Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 21
- +3 vs. Q2 2023
- Shares held
- 6.59M
- +3.54M (+115.6%) vs. Q2 2023
- Total value
- $9.20M
- +$1.99M (+27.5%) vs. Q2 2023
- New holders
- 6
- 3 more added
- Sold out
- 3
- 6 more reduced
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ELUT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 39 | $13.8M |
| Q1 2026 | 35 | $16.0M |
| Q4 2025 | 33 | $11.1M |
| Q3 2025 | 31 | $16.1M |
| Q2 2025 | 28 | $34.4M |
| Q1 2025 | 31 | $43.6M |
| Q4 2024 | 32 | $49.3M |
| Q3 2024 | 29 | $46.7M |
| Q2 2024 | 26 | $44.5M |
| Q1 2024 | 22 | $17.9M |
| Q4 2023 | 24 | $14.9M |
| Q3 2023 | 21 | $9.20M |
| Q2 2023 | 19 | $7.23M |
| Q1 2023 | 18 | $4.20M |
| Q4 2022 | 19 | $18.4M |
| Q3 2022 | 17 | $24.0M |
| Q2 2022 | 17 | $23.6M |
| Q1 2022 | 17 | $19.4M |
| Q4 2021 | 15 | $19.8M |
| Q3 2021 | 17 | $13.2M |
| Q2 2021 | 24 | $19.7M |
| Q1 2021 | 31 | $23.5M |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Elutia Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 108 | $0 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 1 | $1 | 0.00% | +1 | New |
| Wells Fargo & Company | 54 | $77 | 0.00% | −5−8.5% | Reduced |
| UBS Group AG | 500 | $715 | 0.00% | 00.0% | Unchanged |
| US Bancorp | 625 | $894 | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 1,691 | $2.42K | 0.00% | +1,691 | New |
| JPMorgan Chase & Co | 3,702 | $5.29K | 0.00% | +3,702 | New |
| BlackRock Inc. | 14,255 | $20.4K | 0.00% | −560−3.8% | Reduced |
| Verdence Capital Advisors LLC | 14,410 | $20.6K | 0.00% | 00.0% | Unchanged |
| Worth Venture Partners, LLC | 15,428 | $22.1K | 0.01% | +15,428 | New |
| Prosight Management, LP | 25,594 | $36.6K | 0.01% | −298,831−92.1% | Reduced |
| Indie Asset Partners, LLC | 27,000 | $38.6K | 0.04% | +500+1.9% | Added |
| Renaissance Technologies LLC | 29,516 | $42.0K | 0.00% | −30,900−51.1% | Reduced |
| Knollwood Investment Advisory, LLC | 58,962 | $84.3K | 0.04% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 69,637 | $99.6K | 0.00% | +68+0.1% | Added |
| Vanguard Group Inc | 253,374 | $362.3K | 0.00% | −1,483−0.6% | Reduced |
| Perkins Capital Management Inc | 347,198 | $496.0K | 0.49% | −1,750−0.5% | Reduced |
| Alyeska Investment Group, L.P. | 663,244 | $942.5K | 0.01% | +448,901+209.4% | Added |
| AIGH Capital Management LLC | 1,764,000 | $2.30M | 1.09% | +1,764,000 | New |
| Nantahala Capital Management, LLC | 1,650,000 | $2.36M | 0.30% | +1,650,000 | New |
| Birchview Capital, LP | 1,655,184 | $2.37M | 2.01% | 00.0% | Unchanged |
| Millennium Management LLC | 0 | $0 | 0.00% | −13,302−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −1,260−100.0% | Sold out |
| WealthPLAN Partners, LLC | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| BerganKDV Wealth Management, LLC | – | – | – | – | Not filed |